Home FOREIGN Italy Develops Vaccine For Novel Coronavirus, Human Trial Soon

Italy Develops Vaccine For Novel Coronavirus, Human Trial Soon

The End of coronavirus on the crust of mortals could have its elimination fully incepted very soon as scientists from Rome’s Lazzaro Spallanzani Hospital, who are  specialists in studying infectious diseases, said that they have successfully developed a vaccine which neutralises the novel coronavirus in human cells.

This was disclosed when Chief Executive of Takis, Luigi Aurisicchio, the firm working on the treatment, told Italian news agency that tests carried out on mice created antibodies after just one vaccine, which they expect to also work in human trials.

“This is the most advanced stage of testing of a candidate vaccine created in Italy,” Aurisicchio further added that “as far as we know we are the first in the world so far to have demonstrated a neutralisation of the coronavirus by a vaccine”.

The Italian researchers aim to make the vaccine “available to everyone”.Human trials are expected to take place after the summer, he told the outlet.

See also:  Nigerian Govt Complains Of Scarcity Of Healthcare Workers, Blames It On Exodus

While the researchers are developing the vaccine with “Italian research with an all-Italian and innovative technology, tested in Italy” he noted that the vaccine, if successful, will be made available to all citizens.

“In order to reach this goal, we need the support of national and international institutions and partners who may help us speed up the process.”

The researchers worked on developing a vaccine which centred around the coronavirus’s ‘spike’ DNA protein which it uses to latch on to and enter human cells, and so far the trials are proving very promising.

However the vaccine is currently facing observation on its immunity duration. Meanwhile in the United Kingdom, human trials have begun on a vaccine developed at Oxford University’s Jenner Institute, As scientists claimed that the vaccine would be made available in September.

Leave a Reply